This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
14actual
Sites
3
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-20 | actual | When the study began enrolling |
| Primary completion | 2026-08-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-06 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity/Overweight
Interventions
- Drug: AZD6234
- Drug: Placebo
- Drug: AZD9550
- Drug: Plocebo
- Drug: AZD6234 in combination with AZD9550
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumbers of participant with Adverse Events (AEs) and Serious adverse events (SAEs) (sub-study 1).
measured From baseline to Day 141
Numbers of participant with Adverse Events (AEs) and Serious adverse events (SAEs) (sub-study 2).
measured From baseline to Day 225
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed